OptionsHouse

Options Trading News

January 11, 2013  Fri 7:36 AM CT

DNDN: SEE CHART GET CHAIN FIND STRATEGIES
Drug Maker Raised to Outperform

Dendreon was upgraded to "outperform" from "market perform" by Sanford C. Bernstein, which also raised its target price on the drug maker to $10 from $7. DNDN climbs 14 percent before the bell on my tradeMONSTER platform.

Xyratex Earnings Miss the Mark

Xyratex reported a fourth-quarter loss of $0.32, wider than the $0.24 expected by analysts. It additionally forecast first-quarter revenue of $159 million to $189 million, below the $207 million consensus estimate. XRTX is down 4 percent in the premarket.

ArQule Drops on Phase 2 Trial Results

ArQule announced that its tivantinib cancer drug failed to meet its primary endpoint in a randomized phase 2 trial. Development of the compound continues, but ARQL is down 20 percent in early trading.
Share this article with your friends


OptionsHouse

Premium Services

Archived Webinar

Education & Strategy

Real vs. Synthetic

We now know that there are two ways of creating a call position, a put position, and a stock position. We can simply use the actual real security or we can recreate it synthetically. We can create these positions in both long and short forms and this ability sets up an interesting scenario--an arbitrage!

View more education articles »